Involvement of cannabinoid CB2 receptors in the IgE-mediated triphasic cutaneous reaction in mice

Life Sciences

Volumn 80, Issue 5, 2007, Pages 414-419

  Ueda, Yoshifumi ^a   Miyagawa, Naoki ^a   Wakitani, Korekiyo ^a  

^a JAPAN TOBACCO INC   (Japan)

Author keywords

Cannabinoid CB2 receptor; Cutaneous reaction; IgE; Inverse agonist; JTE 907

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; ETHER; IMMUNOGLOBULIN E; JTE 907; N (BENZO[1,3]DIOXOL 5 YLMETHYL) 7 METHOXY 2 OXO 8 PENTYLOXY 1,2 DIHYDROQUINOLINE 3 CARBOXAMIDE; UNCLASSIFIED DRUG; 1 FLUORO 2,4 DINITROBENZENE; 1,3 DIOXOLANE DERIVATIVE; BORNANE DERIVATIVE; LIGAND; MONOCLONAL ANTIBODY; PYRAZOLE DERIVATIVE; QUINOLONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; C57BL 6 MOUSE; CONTROLLED STUDY; DOSE RESPONSE; EAR; EAR DISEASE; EAR SWELLING; FEMALE; MOUSE; MOUSE STRAIN; NONHUMAN; PATCH TEST; SKIN ALLERGY; SKIN MANIFESTATION; SWELLING; WILD TYPE; ANIMAL; ATOPIC DERMATITIS; C57BL MOUSE; DRUG EFFECT; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; PHYSIOLOGY; SKIN;

ANIMALS; ANTIBODIES, MONOCLONAL; BORNANES; DERMATITIS, ATOPIC; DINITROFLUOROBENZENE; DIOXOLES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; IMMUNOGLOBULIN E; LIGANDS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; PYRAZOLES; QUINOLONES; RECEPTOR, CANNABINOID, CB2; SKIN;

EID: 33845811458     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2006.09.026     Document Type: Article

References (49)

1. Berdyshev E.V. Cannabinoid receptors and the regulation of immune response. Chemistry and Physics of Lipids 108 (2000) 169-190
2. Berdyshev E.V., Schmid P.C., Krebsbach R.J., and Schmid H.H. Activation of PAF receptors results in enhanced synthesis of 2-arachidonoylglycerol (2-AG) in immune cells. The FASEB Journal 15 (2001) 2171-2178
3. Bisogno T., MacCarrone M., De Petrocellis L., Jarrahian A., Finazzi-Agro A., Hillard C., and Di Marzo V. The uptake by cells of 2-arachidonoylglycerol, an endogenous agonist of cannabinoid receptors. European Journal of Biochemistry 268 (2001) 1982-1989
4. 2 receptor. European Journal of Pharmacology 396 (2000) 141-149
5. Casanova M.L., Blazquez C., Martinez-Palacio J., Villanueva C., Fernandez-Acenero M.J., Huffman J.W., Jorcano J.L., and Guzman M. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. The Journal of Clinical Investigation 111 (2003) 43-50
6. De Petrocellis L., Melck D., Bisogno T., and Di Marzo V. Endocannabinoids and fatty acid amides in cancer, inflammation and related disorders. Chemistry and Physics of Lipids 108 (2000) 191-209
7. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., and Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258 (1992) 1946-1949
8. Di Marzo V., Melck D., De Petrocellis L., and Bisogno T. Cannabimimetic fatty acid derivatives in cancer and inflammation. Prostaglandins and Other Lipid Mediators 61 (2000) 43-61
9. Facci L., Dal Toso R., Romanello S., Buriani A., Skaper S.D., and Leon A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proceedings of the National Academy of Sciences of the United States of America 92 (1995) 3376-3380
10. Gonsiorek W., Lunn C., Fan X., Narula S., Lundell D., and Hipkin R.W. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. Molecular Pharmacology 57 (2000) 1045-1050
11. Hanus L., Breuer A., Tchilibon S., Shiloah S., Goldenberg D., Horowitz M., Pertwee R.G., Ross R.A., Mechoulam R., and Fride E. HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proceedings of the National Academy of Sciences of the United States of America 96 (1999) 14228-14233
12. Hillard C.J. Biochemistry and pharmacology of the endocannabinoids arachidonylethanolamide and 2-arachidonylglycerol. Prostaglandins and Other Lipid Mediators 61 (2000) 3-18
13. Hollister L.E. Marijuana and immunity. Journal of Psychoactive Drugs 24 (1992) 159-164
14. Inagaki N., Sakurai T., Abe T., Musoh K., Kawasaki H., Tsunematsu M., and Nagai H. Characterization of antihistamines using biphasic cutaneous reaction in BALB/c mice. Life Sciences 63 (1998) PL145-PL150
15. Inagaki N., Shibata T., Itoh T., Suzuki T., Tanaka H., Nakamura T., Akiyama Y., Kawagishi H., and Nagai H. Inhibition of IgE-dependent mouse triphasic cutaneous reaction by a boiling water fraction separated from mycelium of Phellinus linteus. Evidence-Based Complementary and Alternative Medicine 2 (2005) 369-374
16. 2 receptor. The Journal of Pharmacology and Experimental Therapeutics 296 (2001) 420-425
17. Jorda M.A., Verbakel S.E., Valk P.J., Vankan-Berkhoudt Y.V., Maccarrone M., Finazzi-Agro A., Lowenberg B., and Delwel R. Hematopoietic cells expressing the peripheral cannabinoid receptor migrate in response to the endocannabinoid 2-arachidonoylglycerol. Blood 99 (2002) 2786-2793
18. 2 receptor-dependent mechanism. The Journal of Biological Chemistry 278 (2003) 24469-24475
19. Klein T.W., Newton C., and Friedman H. Cannabinoid receptors and immunity. Immunology Today 19 (1998) 373-381
20. Liu J., Batkai S., Pacher P., Harvey-White J., Wagner J.A., Cravatt B.F., Gao B., and Kunos G. Lipopolysaccharide induces anandamide synthesis in macrophages via CD14/MAPK/phosphoinositide 3-kinase/NF-kappaB independently of platelet-activating factor. The Journal of Biological Chemistry 278 (2003) 45034-45039
21. Lunn C.A., Fine J.S., Rojas-Triana A., Jackson J.V., Fan X., Kung T.T., Gonsiorek W., Schwarz M.A., Lavey B., Kozlowski J.A., Narula S.K., Lundell D.J., Hipkin R.W., and Bober L.A. A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo. The Journal of Pharmacology and Experimental Therapeutics 316 (2006) 780-788
22. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., and Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346 (1990) 561-564
23. Mechoulam R., Ben-Shabat S., Hanus L., Ligumsky M., Kaminski N.E., Schatz A.R., Gopher A., Almog S., Martin B.R., Compton D.R., et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochemical Pharmacology 50 (1995) 83-90
24. Munro S., Thomas K.L., and Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365 (1993) 61-65
25. Musoh K., Nakamura N., Ueda Y., Inagaki N., and Nagai H. Possible role of nitric oxide in IgE-mediated allergic cutaneous reaction in mice. International Archives of Allergy and Immunology 115 (1998) 91-96
26. Nagai H., Sakurai T., Inagaki N., and Mori H. An immunopharmacological study of the biphasic allergic skin reaction in mice. Biological and Pharmaceutical Bulletin 18 (1995) 239-245
27. Nagai H., Hiyama H., Matsuo A., Ueda Y., Inagaki N., and Kawada K. FK-506 and cyclosporin A potentiate the IgE antibody production by contact sensitization with hapten in mice. The Journal of Pharmacology and Experimental Therapeutics 283 (1997) 321-327
28. Nagai H., Matsuo A., Hiyama H., Inagaki N., and Kawada K. Immunoglobulin E production in mice by means of contact sensitization with a simple chemical, hapten. The Journal of Allergy and Clinical Immunology 100 (1997) S39-S44
29. Nagai H., Ueda Y., Ochi T., Hirano Y., Tanaka H., Inagaki N., and Kawada K. Different role of IL-4 in the onset of hapten-induced contact hypersensitivity in BALB/c and C57BL/6 mice. British Journal of Pharmacology 129 (2000) 299-306
30. Oka S., Ikeda S., Kishimoto S., Gokoh M., Yanagimoto S., Waku K., and Sugiura T. 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces the migration of EoL-1 human eosinophilic leukemia cells and human peripheral blood eosinophils. Journal of Leukocyte Biology 76 (2004) 1002-1009
31. 2 receptor and its endogenous ligand 2-arachidonoylglycerol in 12-O-tetradecanoylphorbol-13-acetate-induced acute inflammation in mouse ear. The Journal of Biological Chemistry 280 (2005) 18488-18497
32. Pertwee R.G. Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development. Expert Opinion on Investigational Drugs 9 (2000) 1553-1571
33. Pettit D.A., Anders D.L., Harrison M.P., and Cabral G.A. Cannabinoid receptor expression in immune cells. Advances in Experimental Medicine and Biology 402 (1996) 119-129
34. Piomelli D., Giuffrida A., Calignano A., and Rodriguez de Fonseca F. The endocannabinoid system as a target for therapeutic drugs. Trends in Pharmacological Sciences 21 (2000) 218-224
35. Porter A.C., and Felder C.C. The endocannabinoid nervous system: unique opportunities for therapeutic intervention. Pharmacology and Therapeutics 90 (2001) 45-60
36. Ray M.C., Tharp M.D., Sullivan T.J., and Tigelaar R.E. Contact hypersensitivity reactions to dinitrofluorobenzene mediated by monoclonal IgE anti-DNP antibodies. Journal of Immunology 131 (1983) 1096-1102
37. 2 cannabinoid receptor. The Journal of Pharmacology and Experimental Therapeutics 284 (1998) 644-650
38. 2 cannabinoid receptors in mast cells. Journal of Immunology 170 (2003) 4953-4962
39. 2: a characterization of expression and adenylate cyclase modulation within the immune system. Toxicology and Applied Pharmacology 142 (1997) 278-287
40. 2) on sensory nerve fibers and adnexal structures in human skin. Journal of Dermatological Science 38 (2005) 177-188
41. Stefano G.B., Bilfinger T.V., Rialas C.M., and Deutsch D.G. 2-arachidonyl-glycerol stimulates nitric oxide release from human immune and vascular tissues and invertebrate immunocytes by cannabinoid receptor 1. Pharmacological Research 42 (2000) 317-322
42. Sugiura T., Kondo S., Sukagawa A., Nakane S., Shinoda A., Itoh K., Yamashita A., and Waku K. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochemical and Biophysical Research Communications 215 (1995) 89-97
43. 1 receptor is a 2-arachidonoylglycerol receptor. Structure-activity relationship of 2-arachidonoylglycerol, ether-linked analogues, and related compounds. The Journal of Biological Chemistry 274 (1999) 2794-2801
44. 2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. The Journal of Biological Chemistry 275 (2000) 605-612
45. Tahara E., Satoh T., Watanabe C., Shimada Y., Itoh T., Nagai H., Terasawa K., and Saiki I. A third-phase cutaneous (very late phase) response after elicitation with dinitrofluorobenzene in passively or actively sensitized mice. Allergology International 48 (1999) 265-273
46. 2 receptor inverse agonist, JTE-907, in cutaneous inflammation in mice. European Journal of Pharmacology 520 (2005) 164-171
47. Yamada T., Tahara E., Nagai H., Terasawa K., Tani T., Nunome S., and Saiki I. Effect of some Kampo medicines, including Tokaku-joki-to (Tao-He-Cheng-Qi-Tang), on IgE-mediated triphasic skin reaction in passively sensitized mice. The Journal of Traditional Medicines 17 (2000) 17-25
48. Yamaguchi S., Tomomatsu N., Kagoshima M., Okumoto T., and Komatsu H. Effect of Y-24180, an antagonist at platelet-activating factor (PAF) receptors, on IgE-mediated cutaneous reactions in mice. Inflammation Research 47 (1998) 506-511
49. Walter L., Franklin A., Witting A., Wade C., Xie Y., Kunos G., Mackie K., and Stella N. Nonpsychotropic cannabinoid receptors regulate microglial cell migration. The Journal of Neuroscience 23 (2003) 1398-1405